The Future of Personalised Aesthetic Medicine

Last updated: 9 August 2026

Beyond one-size-fits-all: The personalisation revolution

Aesthetic medicine is entering an era of unprecedented personalisation. Where once a standard set of treatments was applied to all patients presenting with similar concerns, advances in genetics, biomarker analysis, artificial intelligence, and manufacturing technology are enabling truly individualised treatment plans tailored to each patient’s unique biology, ageing trajectory, and aesthetic preferences.

We have always practised personalised care, every treatment plan is designed around individual assessment. However, the tools available for personalisation are advancing rapidly, and the coming decade promises to transform what “personalised aesthetic medicine” means in practice.

Genomics and skin ageing

Genetic testing is beginning to move from research laboratories into clinical practice. Several companies now offer skin-specific genetic panels that assess variants in genes affecting collagen metabolism (COL1A1, COL3A1), antioxidant capacity (SOD2, CAT, GPX1), inflammation tendency (TNF-alpha, IL-6, IL-1 beta), pigmentation risk (MC1R, TYR, SLC24A5), and sun sensitivity (HERC2/OCA2).

Research published in the Journal of Investigative Dermatology (2023) validated a 150-gene skin ageing panel that could predict an individual’s primary ageing pathway, categorising patients as predominantly “collagen degraders,” “oxidative agers,” “glycation-prone,” or “inflammation-dominant.” Each category implies different optimal prevention and treatment strategies.

Clinical Application

A patient identified as a “collagen degrader” would benefit most from early and aggressive collagen-stimulating treatments (biostimulators, microneedling), while an “oxidative ager” would gain more from high-potency antioxidant skincare and treatments that support mitochondrial function. Genetic profiling is not yet standard practice, the evidence base is growing but not yet sufficient for definitive treatment recommendations. However, it is a direction of travel that will increasingly influence clinical decision-making.

Biomarker-guided treatment

Beyond genetics, real-time biomarker assessment is enabling more precise treatment timing and product selection:

Skin quality measurement

Advanced diagnostic devices now measure multiple skin parameters simultaneously. Multi-probe systems can quantify hydration levels (corneometry), barrier function (TEWL), elasticity (cutometry), melanin density (mexametry), erythema (spectrophotometry), and sebum production (sebimetry).

These objective measurements enable baseline quantification of skin health, treatment response tracking over time, identification of subclinical problems before they become visible, and evidence-based treatment selection based on measured deficits.

Hormonal Profiling

Understanding individual hormonal status enables treatment optimisation. Salivary cortisol profiles, serum oestrogen and testosterone levels, and thyroid function tests provide context for treatment timing, product selection, and expected outcomes. As discussed in our article on hormonal changes and skin ageing, hormonal status fundamentally influences skin biology and treatment response.

Artificial intelligence in aesthetic planning

AI technology is rapidly advancing in aesthetic medicine. Current applications and near-future developments include:

Facial analysis and simulation

AI-powered facial analysis software can now perform automated facial proportional analysis, identifying deviations from optimal ratios; 3D treatment simulation, showing patients predicted outcomes before treatment; ageing trajectory modelling, predicting how an individual face will age based on current analysis, genetic factors, and lifestyle inputs; and treatment outcome prediction, estimating likely results based on databases of thousands of previous treatment outcomes.

Research from Stanford University (2024) demonstrated that AI facial analysis agreed with expert aesthetic practitioners on treatment recommendations in 78% of cases, and identified concerns that practitioners missed in 12% of cases, particularly subtle asymmetries and proportional imbalances.

Image-based skin diagnostics

AI systems trained on dermatological image databases can identify skin conditions, quantify photodamage severity, track treatment progress through standardised photography, and detect early signs of pathology (melanoma screening). These tools augment rather than replace clinical assessment, but they add consistency, objectivity, and the ability to detect subtle changes that may escape visual inspection.

Custom formulation and compounding

The era of one-product-fits-all skincare is evolving towards individually compounded formulations:

Prescription Compounding

Compounding pharmacies can now produce personalised topical formulations combining active ingredients at specific concentrations tailored to an individual’s needs. For example, a patient with rosacea-prone skin, early melasma, and early fine lines might receive a custom formulation combining azelaic acid (15%), niacinamide (5%), and retinaldehyde (0.05%), a combination not available in any single commercial product.

On-Demand Manufacturing

Emerging technologies are enabling on-site or near-site production of personalised skincare. AI-driven formulation systems assess skin diagnostics and generate custom recipes that are produced on demand. While still in early commercial stages, this approach has been validated in clinical trials showing superior outcomes compared to standard product recommendations.

Microbiome-informed treatments

The skin microbiome, the ecosystem of bacteria, fungi, viruses, and mites living on and within the skin, is increasingly recognised as a critical factor in skin health and treatment response. Emerging microbiome-informed approaches include microbiome profiling, where sequencing an individual’s skin microbiome composition identifies dysbiosis patterns associated with specific skin conditions, and probiotic or postbiotic treatments targeted to restore beneficial microbial populations.

Research in Nature Reviews Microbiology (2023) identified distinct microbiome signatures associated with acne susceptibility, rosacea, and accelerated ageing, suggesting that microbiome modulation could become a core component of personalised aesthetic care.

Pharmacogenomics in Aesthetics

Pharmacogenomics, how genetic variation affects drug response, has implications for aesthetic medicine. Individual variation in enzymes that metabolise botulinum toxin, metabolic rate affecting filler longevity, inflammatory response genes influencing post-treatment recovery, and pain perception genetics affecting treatment experience could all be informed by genetic profiling. A pilot study in Aesthetic Surgery Journal (2024) found that genetic variants in the FCER1A gene correlated with botulinum toxin duration, patients with certain variants experienced effects lasting 5–6 months versus the typical 3–4 months.

Challenges and ethical considerations

The personalisation revolution also raises important questions:

• Evidence threshold: When is a new personalisation technology sufficiently validated for clinical use? The enthusiasm for precision medicine must be tempered by rigorous evidence standards.
• Data privacy: Genetic, biometric, and health data require robust protection. Patients should understand how their data is stored, used, and shared.
• Cost and access: Personalised approaches may initially be more expensive, raising equity concerns. As technologies mature and scale, costs should decrease.
• Over-medicalisation: The ability to measure and analyse must not lead to pathologising normal variation. Not every identified “deficit” requires treatment.

Personalisation Today

While some of the technologies described above are still emerging, the principles of personalised medicine are already central to our practice. Every patient receives a comprehensive facial and skin analysis, detailed medical and lifestyle history assessment, treatment plans designed around their individual biology, concerns, and goals, regular reassessment and plan adjustment based on treatment response, and honest discussion of what is achievable for their unique situation.

Key Takeaways

• Personalised aesthetic medicine is evolving from clinical intuition to data-driven precision
• Genetic profiling, biomarker measurement, and AI analysis are enabling more targeted treatment
• Custom skincare formulations are becoming increasingly viable and validated
• The skin microbiome is an emerging frontier in personalised skin health
• Evidence standards and ethical considerations must keep pace with technological advances